DiaMedica Therapeutics Inc (DMAC)


Stock Price Forecast

March 18, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading DiaMedica Therapeutics Inc chart...

About the Company

diamedica therapeutics is a clinical-stage biopharmaceutical company that is developing innovative treatments where there is significant unmet clinical need or where no current therapies are available with the focus on neurological and kidney diseases. for more information please visit www.diamedica.com.

Exchange

NASDAQ

Website

diamedica.com

$1M

Total Revenue

60

Employees

$108M

Market Capitalization

-4.15

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $DMAC News

DiaMedica Therapeutics Inc DMAC

5d ago, source: Morningstar

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

DiaMedica Therapeutics Inc. (DMAC) stock forecast and price target

8mon ago, source: Yahoo Finance

Find the latest DiaMedica Therapeutics Inc. DMAC analyst stock forecast, price target, and recommendation trends with in-depth analysis from research reports.

Private Ab Tomeqt's Net Worth

1mon ago, source: Benzinga.com

Private Ab Tomeqt has an estimated net worth of $8.33 Million. This is based on reported shares in DiaMedica Therapeutics Inc.. Attention insiders: Dive deeper into market movements and stay ahead ...

Ab Tomenterprise's Net Worth

1mon ago, source: Benzinga.com

Ab Tomenterprise has an estimated net worth of $7.4 Million. This is based on reported shares in DiaMedica Therapeutics Inc.. Attention insiders: Dive deeper into market movements and stay ahead ...

G1 Therapeutics, Inc. (NASDAQ:GTHX) Q4 2023 Earnings Call Transcript

19d ago, source: Yahoo Finance

G1 Therapeutics, Inc. (NASDAQ:GTHX) Q4 2023 Earnings Call Transcript February 28, 2024 G1 Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.21, expectations were $-0.27.

VIGL Vigil Neuroscience, Inc.

5d ago, source: Seeking Alpha

Vigil Neuroscience, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia ...

DiaMedica Therapeutics Inc.

3y ago, source: CNN

DiaMedica Therapeutics, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of novel recombinant proteins. It develops the DM199 product candidate ...

DiaMedica Therapeutics Inc. Common Stock (DMAC)

5y ago, source: Nasdaq

*Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change. **Green highlights the top performing ETF by % change in the past ...

DiaMedica Therapeutics Inc DMAC

21d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

DiaMedica Therapeutics Inc. (DMAC)

1y ago, source: Yahoo Finance

*Close price adjusted for splits.**Adjusted close price adjusted for splits and dividend and/or capital gain distributions. Loading more data ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...